Cargando…
Three-year Efficacy and Safety of Takeda’s Dengue Vaccine Candidate (TAK-003)
BACKGROUND: Takeda’s live attenuated tetravalent dengue vaccine candidate (TAK-003) is under evaluation in a long-term clinical trial across 8 dengue-endemic countries. Previously, we have reported its efficacy and safety in both seronegative and seropositive participants and that its performance va...
Autores principales: | Rivera, Luis, Biswal, Shibadas, Sáez-Llorens, Xavier, Reynales, Humberto, López-Medina, Eduardo, Borja-Tabora, Charissa, Bravo, Lulu, Sirivichayakul, Chukiat, Kosalaraksa, Pope, Martinez Vargas, Luis, Yu, Delia, Watanaveeradej, Veerachai, Espinoza, Felix, Dietze, Reynaldo, Fernando, LakKumar, Wickramasinghe, Pujitha, Duarte MoreiraJr, Edson, Fernando, Asvini D, Gunasekera, Dulanie, Luz, Kleber, Venâncioda Cunha, Rivaldo, Rauscher, Martina, Zent, Olaf, Liu, Mengya, Hoffman, Elaine, LeFevre, Inge, Tricou, Vianney, Wallace, Derek, Alera, MariaTheresa, Borkowski, Astrid |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9402653/ https://www.ncbi.nlm.nih.gov/pubmed/34606595 http://dx.doi.org/10.1093/cid/ciab864 |
Ejemplares similares
-
Efficacy of a Dengue Vaccine Candidate (TAK-003) in Healthy Children and Adolescents 2 Years after Vaccination
por: López-Medina, Eduardo, et al.
Publicado: (2020) -
Effect of the Tetravalent Dengue Vaccine TAK-003 on Sequential Episodes of Symptomatic Dengue
por: Sáez-Llorens, Xavier, et al.
Publicado: (2023) -
Bridging the immunogenicity of a tetravalent dengue vaccine (TAK-003) from children and adolescents to adults
por: LeFevre, Inge, et al.
Publicado: (2023) -
97. Tetravalent Dengue Vaccine (TAK-003) Development Program: A Bird’s Eye View
por: Tricou, Vianney, et al.
Publicado: (2021) -
Commentary on CAM and NK Cells by Kazuyoshi Takeda and Ko Okumura
por: Cooper, Edwin L.
Publicado: (2004)